Plixorafenib

DB16038InvestigationalSmall molecule

PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase B-raf
Curator reviewed
Formula / weight: C₂₅H₂₁F₃N₆O₃S · 542.54 g/mol (avg)
Code names: FORE8394 · PLX-8394

Resolves to

Compound

UNIIJ2L7Z273SGCAS1393466-87-9ChEMBLCHEMBL4303729

Structure

InChIKeyYYACLQUDUDXAPA-MRXNPFEDSA-NSMILESF[C@@H]1CCN(C1)S(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CN=C(N=C2)C2CC2)=C1F

Targets

P15056BRAF

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Plixorafenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account